Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 9/20 | 0.56 |
| ▸ | LCAT | P04180 | 2/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16769744 | 0.89 | LCAT (0.47) | ACACBLCATHRH3CHRNB2CHRNB4 | |
| SCHEMBL16769739 | 0.85 | CHRNB2 (0.54) | ACACBLCATCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL16648701 | 0.84 | MAPT (0.54) | ACACB | |
| SCHEMBL16769749 | 0.81 | ACACB (0.57) | ACACBLCATHRH3 | |
| SCHEMBL16769734 | 0.78 | HRH3 (0.48) | ACACBLCATHRH3 | |
| SCHEMBL3104376 | 0.75 | CHRNB2 (0.63) | ACACBLCATCHRNB2CHRNA4 | |
| SCHEMBL1441410 | 0.75 | CHRNB2 (0.54) | LCATCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL16769754 | 0.75 | LCAT (0.45) | LCATHRH3 | |
| SCHEMBL16769743 | 0.74 | HRH3 (0.48) | ACACBLCATHRH3 | |
| SCHEMBL3104760 | 0.74 | GPR119 (0.60) | ACACBPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150575-B2 | Piperidinylpyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | LCAT, LPL, LCLAT1 | ACACB 209/4885LCAT 1/4885PTGDR 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.